Ezutromid
Ezutromid is a small molecule that was under investigation for its potential use in the treatment of Duchenne Muscular Dystrophy (DMD). DMD is a severe form of muscular dystrophy characterized by rapid progression of muscle degeneration, leading to loss of ambulation and life-threatening complications. Ezutromid aimed to modulate utrophin, a protein similar to dystrophin, which is lacking in individuals with DMD. The hypothesis was that upregulation of utrophin could compensate for the absence of dystrophin, thereby improving muscle function and strength.
Mechanism of Action[edit | edit source]
Ezutromid functions as a utrophin modulation agent. Utrophin is naturally present in all muscles and plays a similar role to dystrophin by stabilizing muscle cell membranes. However, its expression is significantly reduced in mature muscle fibers. Ezutromid's mechanism of action involves the upregulation of utrophin at the muscle membrane, which could potentially substitute for the deficient dystrophin in DMD patients, thus preserving muscle integrity and function.
Clinical Trials[edit | edit source]
Initial clinical trials of ezutromid were focused on assessing its safety, tolerability, and pharmacokinetics in patients with DMD. These early phase studies showed promise, leading to further research in the form of a Phase 2 clinical trial known as the "PhaseOut DMD" trial. This trial aimed to evaluate the efficacy of ezutromid in slowing down the progression of DMD. However, the results from the PhaseOut DMD trial were disappointing. The study did not meet its primary endpoints, and the development of ezutromid for DMD was subsequently discontinued.
Implications for DMD Treatment[edit | edit source]
The discontinuation of ezutromid's development was a setback in the search for effective treatments for DMD. The journey of ezutromid, from its initial promise to the eventual discontinuation, highlights the challenges faced in developing therapies for complex genetic disorders like DMD. Despite this, the research on utrophin modulation as a therapeutic strategy continues, with the hope that new insights and advancements could lead to successful treatments in the future.
See Also[edit | edit source]
 | This medical article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
